A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

The U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...

The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...

One in four women are affected by a UTI in their lifetime ... and a type of staph infection known as Staphylococcus saprophyticus. “The approval of Blujepa is a crucial milestone with uUTIs ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

Staphylococcus saprophyticus and Enterococcus faecalis. Blujepa is the first in a new class of oral antibiotics for uncomplicated urinary tract infections approved in nearly 30 years, GSK's Chief ...

TUESDAY, March 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children ...

A UTI is considered uncomplicated if it occurs ... coli, klebsiella, Citrobacter freundii, Staphylococcus saprophyticus and Enterococcus faecalis. The most common side effects reported from ...